AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event

AIM ImmunoTech (NYSE American: AIM) will host a live virtual investor Closing Bell event on Thursday, February 19, 2026 at 4:00 PM ET featuring CEO Thomas K. Equels.

Rhea-AI Summary

AIM ImmunoTech (NYSE American: AIM) will host a live virtual investor Closing Bell event on Thursday, February 19, 2026 at 4:00 PM ET featuring CEO Thomas K. Equels. The presentation will focus on the lead drug Ampligen and the ongoing DURIPANC trial combining Ampligen with AstraZeneca's Imfinzi for metastatic pancreatic cancer.

A live video webcast will be available on the company Events page, with a replay posted two hours after the live presentation and accessible for 90 days.

Argus Feb 12 session

-6.36% close to close 0.1x rel. volume Open Argus

Details

News Market Reaction – AIM

On Feb 12, the day this news came out, AIM closed 6.36% below the previous close.

Data tracked by StockTitan Argus for the Feb 12 session.

Key Figures

Event date and time: February 19, 2026 at 4:00 PM ET Replay availability: 90 days Replay delay: Two hours

Event date and time

February 19, 2026 at 4:00 PM ET

Scheduled Virtual Investor Closing Bell Event

Replay availability

90 days

Webcast replay access period after the presentation

Replay delay

Two hours

Time after live event before webcast replay becomes available

Historical Context

5 past events · Latest: Feb 11

5 events

1. Feb 11

   Rights offering launch

   24h Move

   -13.5%

   Commencement of rights offering to raise up to $12.0M via Units.

2. Feb 06

   IR webinar participation

   24h Move

   -7.3%

   Virtual corporate overview and outlook with pancreatic cancer focus.

3. Feb 05

   Clinical interim update

   24h Move

   +16.6%

   Positive Phase 2 DURIPANC interim data for Ampligen plus Imfinzi.

4. Jan 27

   Offering terms amended

   24h Move

   +0.0%

   Amendment of key dates and terms for planned rights offering.

5. Jan 23

   Rights offering terms

   24h Move

   -5.2%

   Announcement of rights offering terms aiming to raise up to $12.0M.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

clinical trial, metastatic pancreatic cancer, immune checkpoint inhibitor, anti-PD-L1

4 terms

clinical trial medical

"with an emphasis on the ongoing DURIPANC clinical trial in collaboration"

A clinical trial is a carefully controlled study in which a new medicine, medical device, or treatment is tested on people to see if it is safe and effective. For investors it matters because trial results determine whether a product can win regulatory approval and reach patients, much like a road test decides if a new car can be sold; positive or negative results can sharply change a company’s prospects and stock value.

metastatic pancreatic cancer medical

"durvalumab) in the treatment of metastatic pancreatic cancer."

A serious form of cancer that began in the pancreas and has spread to other parts of the body, such as the liver or lungs; think of it like a fire that started in one room and has moved through the house. It matters to investors because metastatic disease usually signals advanced illness with limited treatment options, influencing the commercial prospects of therapies, clinical trial success, healthcare costs, and the financial outlook for companies working on diagnostics or treatments.

immune checkpoint inhibitor medical

"AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab)"

An immune checkpoint inhibitor is a type of medicine that helps the body's immune system recognize and attack cancer cells more effectively. It works by blocking certain signals that cancer uses to hide from immune defenses, allowing the immune system to target tumors. This breakthrough has led to new cancer treatments, making immune checkpoint inhibitors an important area of growth and innovation in the healthcare industry.

anti-PD-L1 medical

"AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab)"

An anti-PD-L1 is a type of antibody drug that blocks the PD-L1 protein tumors use to hide from the immune system; by removing this “invisibility cloak,” it helps immune cells recognize and attack cancer. For investors, anti-PD-L1 therapies matter because clinical trial results, regulatory approvals, safety profiles, and how broadly they work across cancer types directly affect a drug’s commercial potential, pricing, and a company’s valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, February 19th at 4:00 PM ET

Event to focus on lead program, Ampligen, for treatment of pancreatic cancer

OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will participate in a Virtual Investor Closing Bell Event on Thursday, February 19, 2026, at 4:00 PM ET.

Equels will focus on AIM’s clinical and regulatory strategy for its lead drug Ampligen, with an emphasis on the ongoing DURIPANC clinical trial in collaboration with AstraZeneca combining Ampligen and AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer.

A live video webcast of the presentation will be available on the Events page of the Company’s website (aimimmuno.com). A webcast replay will become available two hours following the live presentation and will be accessible for 90 days.

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of its lead product, Ampligen^® (rintatolimod), for the treatment of late-stage pancreatic cancer, a lethal and unmet global health problem. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials.

For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.

Investor Contact:

JTC Team, LLC
Jenene Thomas
908.824.0775
AIM@jtcir.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is AIM (AIM) hosting the virtual Closing Bell event and who will present?

The event is on February 19, 2026 at 4:00 PM ET, presented by CEO Thomas K. Equels. According to the company, Equels will discuss clinical and regulatory strategy for Ampligen and the DURIPANC trial with AstraZeneca's Imfinzi.

What will AIM (AIM) discuss about Ampligen during the February 19, 2026 webcast?

The company will focus on clinical and regulatory strategy for Ampligen, emphasizing the DURIPANC trial. According to the company, discussion covers combining Ampligen with AstraZeneca's anti-PD-L1 therapy Imfinzi in metastatic pancreatic cancer.

How can investors watch the AIM (AIM) live webcast on February 19, 2026?

Investors can view the live video webcast on the company's Events page. According to the company, the webcast link will be available on the company's website and open to viewers at the scheduled time.

Will AIM (AIM) provide a replay of the February 19, 2026 Closing Bell event?

Yes. According to the company, a webcast replay will be posted two hours after the live presentation and will remain accessible for 90 days on the Events page for later viewing.

What clinical trial will AIM (AIM) highlight at the February 19, 2026 presentation?

The presentation will highlight the DURIPANC clinical trial combining Ampligen with AstraZeneca's Imfinzi. According to the company, DURIPANC targets the treatment of metastatic pancreatic cancer in collaboration with AstraZeneca.

Does the February 19, 2026 AIM (AIM) event include regulatory strategy details for Ampligen?

Yes. According to the company, CEO Equels will address both clinical and regulatory strategy for Ampligen. The discussion is expected to cover development plans and the role of the DURIPANC combination study with Imfinzi.